Richard J. Berman Sells 7,250 Shares of Cryoport, Inc. (NASDAQ:CYRX) Stock
Cryoport, Inc. (NASDAQ:CYRX – Get Rating) Director Richard J. Berman sold 7,250 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $19.63, for a total value of $142,317.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Cryoport Price Performance
Shares of NASDAQ:CYRX opened at $19.99 on Monday. Cryoport, Inc. has a one year low of $15.79 and a one year high of $70.90. The business’s fifty day moving average price is $22.80 and its two-hundred day moving average price is $28.86. The company has a debt-to-equity ratio of 0.75, a quick ratio of 14.35 and a current ratio of 14.96. The stock has a market cap of $979.51 million, a PE ratio of -3.25 and a beta of 1.21.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Advisors Capital Management LLC boosted its holdings in Cryoport by 54.0% in the third quarter. Advisors Capital Management LLC now owns 75,763 shares of the consumer goods maker’s stock valued at $1,516,000 after acquiring an additional 26,579 shares during the last quarter. Alpha Paradigm Partners LLC boosted its holdings in Cryoport by 18.7% in the third quarter. Alpha Paradigm Partners LLC now owns 69,575 shares of the consumer goods maker’s stock valued at $1,695,000 after acquiring an additional 10,970 shares during the last quarter. BNP Paribas Arbitrage SNC raised its position in Cryoport by 100.0% in the third quarter. BNP Paribas Arbitrage SNC now owns 19,626 shares of the consumer goods maker’s stock valued at $478,000 after purchasing an additional 9,814 shares during the period. Castleark Management LLC purchased a new position in Cryoport in the third quarter valued at about $1,591,000. Finally, Two Sigma Advisers LP purchased a new position in Cryoport in the third quarter valued at about $431,000. Institutional investors and hedge funds own 90.33% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. Needham & Company LLC cut their target price on Cryoport from $49.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 4th. KeyCorp dropped their price objective on Cryoport from $52.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. SVB Leerink lowered their target price on Cryoport from $45.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, November 4th. Finally, B. Riley lowered their target price on Cryoport from $55.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $42.17.
Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Cryoport, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cryoport wasn’t on the list.
While Cryoport currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.